GENinCode Shares Rise on FDA Filing for Heart Disease Test Kit
2023年8月16日 - 8:41PM
Dow Jones News
By Ian Walker
Shares of GENinCode rose 17% after the company said that it has
filed a premarket notification with the U.S. Food and Drug
Administration for its coronary heart disease risk assessment test
kit, Cardio inCode-Score.
Shares at 1106 GMT were up 2.0 pence at 13.50 pence.
The London-listed predictive genetics company said Wednesday
that approval will enable the expansion and commercial distribution
of the device in the U.S.
It expects to receive FDA approval for the device over the next
six months.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 16, 2023 07:26 ET (11:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Genincode (LSE:GENI)
過去 株価チャート
から 5 2024 まで 6 2024
Genincode (LSE:GENI)
過去 株価チャート
から 6 2023 まで 6 2024